Grundläggande statistik
| CIK | 1355790 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to International Stem Cell Corporation
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| September 16, 2025 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 15, 2025 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commissio |
|
| September 16, 2025 |
INTERNATIONAL STEM CELL CORPORATION PROMISSORY NOTE (EXTENSION) Exhibit 10.1 INTERNATIONAL STEM CELL CORPORATION PROMISSORY NOTE (EXTENSION) FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, on this 15th day of September, 2025 (the “Issuance Date”), International Stem Cell Corporation, a Delaware corporation, with offices located at 9745 Businesspark Ave, San Diego, CA (the “Borrower”), hereby unconditionally promises to pay to the |
|
| August 14, 2025 |
Exhibit 10.1 Co-Tenant Agreement Amendment This Co-Tenant Agreement Amendment is hereby made as of February 25, 2025, into by and between International Stem Cell Corporation (hereinafter referred to as "ISCO") and S Real Estate Holdings, LLC (hereinafter referred to as "SREH"). Collectively, ISCO and SREH are referred to as the "Parties". WHEREAS, On October 26, 2021, PARTIES have entered into a l |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-51891 INTERNATIONAL STEM CELL |
|
| May 14, 2025 |
Exhibit 10.1 Co-Tenant Agreement Amendment This Co-Tenant Agreement Amendment is hereby made as of February 25, 2025, into by and between International Stem Cell Corporation (hereinafter referred to as "ISCO") and S Real Estate Holdings, LLC (hereinafter referred to as "SREH"). Collectively, ISCO and SREH are referred to as the "Parties". WHEREAS, On October 26, 2021, PARTIES have entered into a l |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-51891 INTERNATIONAL STEM CEL |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-51891 INTERNATIONAL STEM CELL CORPORATION (Exact nam |
|
| March 28, 2025 |
Insider Trading Compliance Program Exhibit 19.1 International Stem Cell Corporation Insider Trading Policy Effective Tuesday, June 15, 2021 1. Introduction The Board of Directors of International Stem Cell Corporation, (together with its subsidiaries, the “Company”) has established the rules set forth in this Insider Trading Policy (the “Policy”) in order to provide guidelines to all directors, officers, employees, and consultants |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-51891 INTERNATIONAL STEM |
|
| September 17, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 15, 2024 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commissio |
|
| September 17, 2024 |
Form of Note issued on September 15, 2024 Exhibit 10.1 INTERNATIONAL STEM CELL CORPORATION PROMISSORY NOTE FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, on this 15th day of September, 2024 (the “Issuance Date”), International Stem Cell Corporation, a Delaware corporation, with offices located at 9745 Businesspark Ave, San Diego, CA (the “Borrower”), hereby unconditionally promises to pay to the order of And |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-51891 INTERNATIONAL STEM CELL |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-51891 INTERNATIONAL STEM CEL |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 28, 2024 |
Policy for Recovery of Erroneously Awarded Incentive Compensation Exhibit 97.1 INTERNATIONAL STEM CELL CORPORATION Policy for RECOVERY OF ERRONEOUSLY AWARDED Incentive Compensation (Adopted November 28, 2023) 1. INTRODUCTION International Stem Cell Corporation (the “Company”) is adopting this policy (this “Policy”) to provide for the Company’s recovery of certain Incentive Compensation (as defined below) erroneously awarded to Affected Officers (as defined below |
|
| March 28, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) International Stem Cell Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0. |
|
| March 28, 2024 |
As filed with the Securities and Exchange Commission on March 28, 2024 As filed with the Securities and Exchange Commission on March 28, 2024 Registration No. |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-51891 INTERNATIONAL STEM CELL CORPORATION (Exact nam |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-51891 INTERNATIONAL STEM |
|
| September 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☒ Definitive Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) International Stem Cell Corporation |
|
| September 18, 2023 |
Form of Note issued on September 15, 2023 Exhibit 10.1 INTERNATIONAL STEM CELL CORPORATION PROMISSORY NOTE FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, on this 15th day of September, 2023 (the “Issuance Date”), International Stem Cell Corporation, a Delaware corporation, with offices located at 9745 Businesspark Ave, San Diego, CA (the “Borrower”), hereby unconditionally promises to pay to the order of And |
|
| September 18, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 15, 2023 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commissio |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-51891 INTERNATIONAL STEM CELL |
|
| June 21, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 14, 2023 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-51891 INTERNATIONAL STEM CEL |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 30, 2023 |
2 Ro UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K 2 Ro UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-51891 INTERNATIONAL STEM CELL CORPORATION (Exac |
|
| March 16, 2023 |
Exhibit 10.1 INTERNATIONAL STEM CELL CORPORATION PROMISSORY NOTE FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, on this 15th day of March, 2023 (the “Issuance Date”), International Stem Cell Corporation, a Delaware corporation, with offices located at 9745 Businesspark Ave, San Diego, CA (the “Borrower”), hereby unconditionally promises to pay to the order of Andrey |
|
| March 16, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 15, 2023 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-51891 INTERNATIONAL STEM |
|
| September 16, 2022 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 15, 2022 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commissio |
|
| September 16, 2022 |
Form of Note issued on September 15, 2022 Exhibit 10.1 INTERNATIONAL STEM CELL CORPORATION PROMISSORY NOTE FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, on this 15th day of September, 2022 (the ?Issuance Date?), International Stem Cell Corporation, a Delaware corporation, with offices located at 9745 Businesspark Ave, San Diego, CA (the ?Borrower?), hereby unconditionally promises to pay to the order of And |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-51891 INTERNATIONAL STEM CELL |
|
| June 14, 2022 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 9, 2022 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commission File |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-51891 INTERNATIONAL STEM CEL |
|
| April 29, 2022 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 25, 2022 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 27, 2022 |
DEF 14A 1 isco-def14a20220428.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Comm |
|
| March 29, 2022 |
Lease Agreement dated October 26, 2021 Exhibit 10.12 STANDARD INDUSTRIAL/COMMERCIAL MULTI?TENANT LEASE ? NET 1. Basic Provisions ("Basic Provisions"). 1.1Parties. This Lease ("Lease"), dated for reference purposes only October 19, 2021, is made by and between Rehco Holdings, LLC ("Lessor") and International Stem Cell Corporation & S Real Estate Holdings, LLC ("Lessee"), (collectively the "Parties", or individually a "Party"). 1.2(a)Pre |
|
| March 29, 2022 |
2 Ro UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K 2 Ro UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-51891 INTERNATIONAL STEM CELL CORPORATION (Exac |
|
| March 29, 2022 |
Co-Tenant Agreement dated December 15, 2021 Exhibit 10.14 CO-TENANT AGREEMENT This Co-Tenant Agreement (?Agreement?) is made as of November , 2021 (?Effective Date?) by and between International Stem Cell Corporation, having its principal business of 5950 Priestly Drive, Carlsbad, California 92008 (hereinafter referred to as ?ISCO?) and S REAL ESTATE HOLDINGS, LLC (hereinafter referred to as ?S Real Estate?). Collectively, ISCO and S Real E |
|
| March 29, 2022 |
Lease Agreement dated November 30, 2021 Exhibit 10.13 SCRIPPS RANCH OFFICE LEASE AGREEMENT NAME OF TENANT International Stem Cell Corporation ADDRESS 9747 Businesspark Avenue CITY, STATE, ZIPCODE San Diego, CA 92131 TELEPHONE NUMBER EMAIL This professional office lease (hereinafter ?Lease?) is entered into and executed by and between Tenant whose name appears above (hereinafter ?tenant?) and Rehco Holdings, LLC (hereinafter ?RH?), the o |
|
| March 3, 2022 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 1, 2022 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 3, 2022 |
Form of Note issued on March 1, 2022 Exhibit 10.1 INTERNATIONAL STEM CELL CORPORATION PROMISSORY NOTE FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, on this 1st day of March, 2022 (the ?Issuance Date?), International Stem Cell Corporation, a Delaware corporation, with offices located at 9745 Businesspark Ave, San Diego, CA (the ?Borrower?), hereby unconditionally promises to pay to the order of Andrey S |
|
| February 2, 2022 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 1, 2022 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commission |
|
| January 14, 2022 |
Form of Note issued on January 13, 2022 Exhibit 10.1 INTERNATIONAL STEM CELL CORPORATION PROMISSORY NOTE FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, on this 13th day of January, 2022 (the ?Issuance Date?), International Stem Cell Corporation, a Delaware corporation, with offices located at 9745 Businesspark Ave, San Diego, CA (the ?Borrower?), hereby unconditionally promises to pay to the order of Andre |
|
| January 14, 2022 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 13, 2022 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commission |
|
| December 28, 2021 |
Termination of a Material Definitive Agreement SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 27, 2021 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commission |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-51891 INTERNATIONAL STEM |
|
| November 1, 2021 |
Entry into a Material Definitive Agreement SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 26, 2021 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commission |
|
| August 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-51891 INTERNATIONAL STEM CELL |
|
| June 30, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 25, 2021 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 30, 2021 |
Certificate of Elimination for Series I-1 Preferred Stock Exhibit 3.1 CERTIFICATE OF ELIMINATION OF THE SERIES I-1 PREFERRED STOCK OF INTERNATIONAL STEM CELL CORPORATION Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware International Stem Cell Corporation, a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), in accordance with the provisions of Section 151(g) of the General Cor |
|
| June 14, 2021 |
Submission of Matters to a Vote of Security Holders SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 9, 2021 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commission File |
|
| May 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-51891 INTERNATIONAL STEM CEL |
|
| April 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 30, 2021 |
Promissory Note, dated March 18, 2021, by and between the Company and Endeavor Bank (filed herewith) Exhibit 10.17 U.S. Small Business Administration NOTE SBA Loan # 2487468609 SBA Loan Name International Stem Cell Corporation Date March 18, 2021 Loan Amount $474,147.00 Interest Rate 1.00% Borrower International Stem Cell Corporation Operating Company N/A Lender Endeavor Bank 1. PROMISE TO PAY: In return for the Loan, Borrower promises to pay to the order of Lender the amount of Four hundred and |
|
| March 30, 2021 |
Ro UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-51891 INTERNATIONAL STEM CELL CORPORATION (Exact |
|
| March 30, 2021 |
Exhibit 4.7 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 International Stem Cell Corporation (?ISCO,? ?we,? ?our,? or ?us?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock. DESCRIPTION OF CAPITAL STOCK The following summary of the terms of our capital |
|
| March 8, 2021 |
Form of Note issued on March 5, 2021 Exhibit 10.1 INTERNATIONAL STEM CELL CORPORATION PROMISSORY NOTE FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, on this 5th day of March, 2021 (the ?Issuance Date?), International Stem Cell Corporation, a Delaware corporation, with offices located at 5950 Priestly Drive, Carlsbad, CA 92008 (the ?Borrower?), hereby unconditionally promises to pay to the order of Andre |
|
| March 8, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 5, 2021 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commission Fil |
|
| January 19, 2021 |
Form of Note issued on January 15, 2021 Exhibit 10.1 INTERNATIONAL STEM CELL CORPORATION PROMISSORY NOTE FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, on this 15th day of January, 2021 (the “Issuance Date”), International Stem Cell Corporation, a Delaware corporation, with offices located at 5950 Priestly Drive, Carlsbad, CA 92008 (the “Borrower”), hereby unconditionally promises to pay to the order of An |
|
| January 19, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 15, 2021 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commission |
|
| November 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-51891 INTERNATIONAL STEM |
|
| August 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-51891 INTERNATIONAL STEM CELL |
|
| August 12, 2020 |
Exhibit 10.1 International Stem Cell Corporation 2010 Equity Participation Plan (as amended through June 23, 2020) 1. ESTABLISHMENT, PURPOSE AND TERM OF PLAN. 1.1 Establishment. The International Stem Cell Corporation. 2010 Equity Participation Plan (the “Plan”) is hereby established effective as of March 29, 2010 (the “Effective Date”), the date of its adoption by the Board, subject to the approv |
|
| August 12, 2020 |
Promissory Note, dated May 4, 2020, by and between the Company and Wells Fargo Bank, N.A. Exhibit 10.2 Paycheck Protection Program Promissory Note and Agreement Wells Fargo SBA Lending Borrower Names: International Stem Cell Corporation Important Notice: This Instrument Contains A Confession Of Judgment Provision Which Constitutes A Waiver Of Important Rights You May Have As A Debtor And Allows The Creditor To Obtain A Judgment Against You Without Any Further Notice. Venue Will Be In T |
|
| June 30, 2020 |
8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 23, 2020 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commission |
|
| June 19, 2020 |
Exhibit 10.1 STANDARD MULTI-TENANT OFFICE LEASE This Restated Lease Agreement (the “Lease”) is dated as of March 1, 2020 (the “Effective Date”) is made by and between S Real Estate Holdings LLC, a Delaware limited liability company (“Landlord”) and International Stem Cell Corporation, a Delaware corporation (“Tenant”) (collectively, the “Parties” or individually, a “Party”). 1.Basic Lease Provisio |
|
| June 19, 2020 |
Quarterly Report - ISCO-10Q-20200331 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-51891 INTERNATIONAL STEM CEL |
|
| June 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| June 1, 2020 |
Consent of Mayer Hoffman McCann P.C. Exhibit 23.2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Prospectus constituting a part of the Registration Statements on Form S-8 (Nos. 333-226844, 333-211411, 333-206930, 333-169549, 333-166883, 333-166421, 333-166420, 333-164539, 333-159424, 333-159421, and 333-150920) and on Form S-1 (Nos. 333-210840, 333-201589, and 333-1 |
|
| June 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-51891 INTERNATIONAL STEM CELL CORPORATION (Exact nam |
|
| May 13, 2020 |
NT 10-K SEC File Number: 0-51891 CUSIP Number: 460378 201 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 13, 2020 |
8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 13, 2020 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commission |
|
| April 28, 2020 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 28, 2020 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 30, 2020 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 30, 2020 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commission Fi |
|
| December 19, 2019 |
8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 17, 2019 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commis |
|
| December 19, 2019 |
Form of Note issued on December 17, 2019 EX-10.1 Exhibit 10.1 INTERNATIONAL STEM CELL CORPORATION PROMISSORY NOTE FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, on this 17th day of December, 2019 (the “Issuance Date”), International Stem Cell Corporation, a Delaware corporation, with offices located at 5950 Priestly Drive, Carlsbad, CA 92008 (the “Borrower”), hereby unconditionally promises to pay to the or |
|
| November 12, 2019 |
ISCO / International Stem Cell Corp. 10-Q - Quarterly Report - 10-Q Q3-20190930 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-51891 INTERNATIONAL STEM |
|
| August 27, 2019 |
ISCO / International Stem Cell Corp. 10-Q - Quarterly Report - 10-Q Q2 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-51891 INTERNATIONAL STEM CELL |
|
| August 14, 2019 |
ISCO / International Stem Cell Corp. NT 10-Q - - NT 10-Q NT 10-Q SEC File Number: 0-51891 CUSIP Number: 460378 201 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 30, 2019 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant Form 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 25, 2019 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commi |
|
| July 30, 2019 |
Letter of Mayer Hoffman McCann P.C. to the Securities and Exchange Commission, dated July 26, 2019. EX-16.1 Exhibit 16.1 July 26, 2019 Securities and Exchange Commission 100 First Street, N.E. Washington, D.C. 20549 Ladies and Gentlemen: We have read Item 4.01 of International Stem Cell Corporation’s Form 8-K dated on July 25, 2019, and we agree with the statements set forth in the second, third, fourth and fifth paragraphs of Item 4.01 (a) insofar as they relate to our firm. We have no basis to |
|
| June 7, 2019 |
Form 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 3, 2019 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commis |
|
| May 15, 2019 |
ISCO / International Stem Cell Corp. 10-Q Quarterly Report 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-51891 INTERNATIONAL STEM CEL |
|
| April 30, 2019 |
ISCO / International Stem Cell Corp. DEF 14A DEF 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 23, 2019 |
Form of Note issued on April 17, 2019 EX-10.1 Exhibit 10.1 INTERNATIONAL STEM CELL CORPORATION PROMISSORY NOTE FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, on this 17th day of April, 2019 (the “Issuance Date”), International Stem Cell Corporation, a Delaware corporation, with offices located at 5950 Priestly Drive, Carlsbad, CA 92008 (the “Borrower”), hereby unconditionally promises to pay to the order |
|
| April 23, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits Form 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 17, 2019 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Comm |
|
| April 15, 2019 |
ISCO / International Stem Cell Corp. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-51891 INTERNATIONAL STEM CELL CORPORATION (Exact nam |
|
| April 1, 2019 |
ISCO / International Stem Cell Corp. NT 10-K NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number: 0-51891 CUSIP Number: 460378 201 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2018 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 1 |
|
| March 7, 2019 |
ISCO / International Stem Cell Corp. / X-Master, Inc. - SC 13D AMENDMENT NO. 21 Activist Investment SC 13D Amendment No. 21 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 21) International Stem Cell Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 460378201 (CUSIP Number) Russell Kern, President X-Master, Inc. 1 Overlook Drive, Unit 11 Amherst, New Ha |
|
| March 7, 2019 |
EX-99.1 Exhibit 1 AGREEMENT OF JOINT FILING Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby consent to the joint filing on their behalf of a single Schedule 13D and any amendments thereto, with respect to the beneficial ownership by each of the undersigned of shares of common stock, $0.001 par value, of International Stem Cell Corporation, |
|
| January 23, 2019 |
EX-10.1 Exhibit 10.1 NOTE CONVERSION AGREEMENT THIS NOTE CONVERSION AGREEMENT (this “Agreement”) is made and entered into on this 21 day of January, 2019 (“Effective Date”), by and among International Stem Cell Corporation, a Delaware corporation with offices located at 5950 Priestly Drive, Carlsbad, CA 9008 (the “Company”), and Andrey Semechkin (the “Holder”). RECITALS A. WHEREAS, the Holder is t |
|
| January 23, 2019 |
Form 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 21, 2019 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Co |
|
| November 15, 2018 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 12, 2018 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commis |
|
| November 15, 2018 |
EX-10.1 Exhibit 10.1 FIRST AMENDMENT TO INTERNATIONAL STEM CELL CORPORATION PROMISSORY NOTE THIS FIRST AMENDMENT TO PROMISSORY NOTE (“Amendment”), dated November 12, 2018, is entered into by International Stem Cell Corporation, a Delaware corporation, with offices located at 5950 Priestly Drive, Carlsbad, CA 92008 (the “Borrower”) and Andrey Semechkin or his assigns (the “Noteholder”); WHEREAS, Bo |
|
| November 14, 2018 |
ISCO / International Stem Cell Corp. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-51891 INTERNATIONAL STEM |
|
| October 3, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 27, 2018 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporati |
|
| August 15, 2018 |
ISCO / International Stem Cell Corp. FORM S-8 Form S-8 As filed with the Securities and Exchange Commission on August 14, 2018 Registration No. |
|
| August 14, 2018 |
ISCO / International Stem Cell Corp. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-51891 INTERNATIONAL STEM CELL |
|
| August 14, 2018 |
Form of Note issued on August 8, 2018.* Exhibit 10.4 INTERNATIONAL STEM CELL CORPORATION PROMISSORY NOTE FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, on this 8th day of August, 2018 (the “Issuance Date”), International Stem Cell Corporation, a Delaware corporation, with offices located at 5950 Priestly Drive, Carlsbad, CA 92008 (the “Borrower”), hereby unconditionally promises to pay to the order of Andr |
|
| June 27, 2018 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 21, 2018 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 4, 2018 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 31, 2018 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commission File |
|
| June 4, 2018 |
Form of Note issued on May 31, 2018 EXHIBIT 10.1 INTERNATIONAL STEM CELL CORPORATION PROMISSORY NOTE FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, on this 31st day of May, 2018 (the “Issuance Date”), International Stem Cell Corporation, a Delaware corporation, with offices located at 5950 Priestly Drive, Carlsbad, CA 92008 (the “Borrower”), hereby unconditionally promises to pay to the order of Andrey |
|
| May 21, 2018 |
ISCO / International Stem Cell Corp. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-51891 INTERNATIONAL STEM CEL |
|
| May 16, 2018 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 14, 2018 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commission File |
|
| May 16, 2018 |
Exhibit 10.1 INTERNATIONAL STEM CELL CORPORATION PROMISSORY NOTE FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, on this 14th day of May, 2018 (the “Issuance Date”), International Stem Cell Corporation, a Delaware corporation, with offices located at 5950 Priestly Drive, Carlsbad, CA 92008 (the “Borrower”), hereby unconditionally promises to pay to the order of Andrey |
|
| May 15, 2018 |
ISCO / International Stem Cell Corp. NT 10-Q OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response 2. |
|
| April 30, 2018 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 6, 2018 |
ISCO / International Stem Cell Corp. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-51891 INTERNATIONAL STEM CELL CORPORATION (Exact nam |
|
| April 2, 2018 |
ISCO / International Stem Cell Corp. NT 10-K OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response 2. |
|
| March 8, 2018 |
Exhibit 10.1 INTERNATIONAL STEM CELL CORPORATION PROMISSORY NOTE FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, on this 6th day of March, 2018 (the “Issuance Date”), International Stem Cell Corporation, a Delaware corporation, with offices located at 5950 Priestly Drive, Carlsbad, CA 92008 (the “Borrower”), hereby unconditionally promises to pay to the order of Andre |
|
| March 8, 2018 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 6, 2018 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 8, 2018 |
ISCO / International Stem Cell Corp. RW International Stem Cell Corporation 5950 Priestly Drive Carlsbad, California 92008 March 6, 2018 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Re: International Stem Cell Corporation Registration Statement on Form S-1 (File No. |
|
| February 21, 2018 |
isco-8k20180213.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 13, 2018 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorp |
|
| January 31, 2018 |
ISCO / International Stem Cell Corp. / X-Master, Inc. - AMENDMENT NO. 20 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 20) International Stem Cell Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 460378201 (CUSIP Number) Russell Kern, President X-Master, Inc. 1 Overlook Drive, Unit 11 Amherst, New Hampshire 03031 Tel. (603) |
|
| December 13, 2017 |
isco-ex10144.htm Exhibit 10.1 NOTE CONVERSION AND STOCK PURCHASE AGREEMENT THIS NOTE CONVERSION AND STOCK PURCHASE AGREEMENT (this ?Agreement?) is made as of December 7, 2017, by and among International Stem Cell Corporation, a Delaware corporation (the ?Company?), and Andrey Semechkin (the ?Holder?). RECITALS A.Holder is the Co-Chairman and Chief Executive Officer of the Company, and fully unders |
|
| December 13, 2017 |
isco-8k20171206.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 7, 2017 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorpo |
|
| November 14, 2017 |
ISCO / International Stem Cell Corp. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-51891 INTERNATIONAL STEM |
|
| September 6, 2017 |
isco-ex1016.htm Exhibit 10.1 INTERNATIONAL STEM CELL CORPORATION PROMISSORY NOTE FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, on this 1st day of September, 2017 (the ?Issuance Date?), International Stem Cell Corporation, a Delaware corporation, with offices located at 5950 Priestly Drive, Carlsbad, CA 92008 (the ?Borrower?), hereby unconditionally promises to pay t |
|
| September 6, 2017 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits isco-8k20170901.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 1, 2017 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorp |
|
| August 25, 2017 |
isco-8k20170822.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 22, 2017 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorpor |
|
| August 11, 2017 |
ISCO / International Stem Cell Corp. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-51891 INTERNATIONAL STEM CELL |
|
| June 9, 2017 |
International Stem Cell FORM POSAM isco-s8.htm As filed with the Securities and Exchange Commission on June 9, 2017 Registration No. 333-210840 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Post-Effective Amendment No. 1 to Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 2834 20-4494098 (State |
|
| June 8, 2017 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits isco-8k20170602.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 2, 2017 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporati |
|
| June 8, 2017 |
isco-ex1016.htm Exhibit 10.1 INTERNATIONAL STEM CELL CORPORATION PROMISSORY NOTE FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, on this 2nd day of June, 2017 (the ?Issuance Date?), International Stem Cell Corporation, a Delaware corporation, with offices located at 5950 Priestly Drive, Carlsbad, CA 92008 (the ?Borrower?), hereby unconditionally promises to pay to the |
|
| June 6, 2017 |
isco-8k20170531.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 31, 2017 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporati |
|
| May 15, 2017 |
Exhibit 10.2 FOURTH AMENDMENT TO STANDARD MULTI-TENANT OFFICE LEASE ? GROSS This Fourth Amendment to Standard Multi-Tenant Office Lease - Gross (?4th Amendment?) is made and entered into as of this 1st day of March, 2017 by and between S Real Estate Holdings, LLC (?Lessor?) and International Stem Cell Corporation, a California corporation (?Lessee?), with reference to the following facts: A.Partie |
|
| May 15, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-51891 INTERNATIONAL STEM CEL |
|
| April 27, 2017 |
International Stem Cell DEF 14A isco-def14a20170531.htm SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive A |
|
| March 31, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-51891 INTERNATIONAL STEM CELL CORPORATION (Exact nam |
|
| March 22, 2017 |
isco-ex1016.htm Exhibit 10.1 INTERNATIONAL STEM CELL CORPORATION PROMISSORY NOTE FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, on this 20th day of March, 2017 (the ?Issuance Date?), International Stem Cell Corporation, a Delaware corporation, with offices located at 5950 Priestly Drive, Carlsbad, CA 92008 (the ?Borrower?), hereby unconditionally promises to pay to t |
|
| March 22, 2017 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits isco-8k20170320.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 20, 2017 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorpora |
|
| February 28, 2017 |
Entry into a Material Definitive Agreement isco-8k20170222.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 22, 2017 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorp |
|
| January 18, 2017 |
isco-ex1016.htm Exhibit 10.1 INTERNATIONAL STEM CELL CORPORATION PROMISSORY NOTE FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, on this 12th day of January, 2017 (the ?Issuance Date?), International Stem Cell Corporation, a Delaware corporation, with offices located at 5950 Priestly Drive, Carlsbad, CA 92008 (the ?Borrower?), hereby unconditionally promises to pay to |
|
| January 18, 2017 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits isco-8k20170112.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 12, 2017 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorpo |
|
| December 13, 2016 |
isco-8k20161208.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 8, 2016 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorpo |
|
| November 14, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-51891 INTERNATIONAL STEM |
|
| September 19, 2016 |
Unregistered Sales of Equity Securities isco-8k20160914.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 14, 2016 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incor |
|
| August 24, 2016 |
isco-8k20160822.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 22, 2016 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorpor |
|
| August 24, 2016 |
isco-8k20160822.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 22, 2016 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorpor |
|
| August 15, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q isco-10q20160630.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-51891 IN |
|
| August 15, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q isco-10q20160630.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-51891 IN |
|
| July 6, 2016 |
isco-8k20160629.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 29, 2016 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporat |
|
| May 18, 2016 |
EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF INTERNATIONAL STEM CELL CORPORATION International Stem Cell Corporation, a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?Corporation?), does hereby certify: FIRST: On March 24, 2016, the Board of Directors of the Corporation duly adopted resoluti |
|
| May 18, 2016 |
Form 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 13, 2016 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commis |
|
| May 17, 2016 |
S-8 As filed with the Securities and Exchange Commission on May 17, 2016 Registration No. |
|
| May 16, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-51891 INTERNATIONAL STEM CEL |
|
| May 9, 2016 |
INTERNATIONAL STEM CELL CORPORATION 7,999,999 Shares of Common Stock 424B4 Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-210840 PROSPECTUS INTERNATIONAL STEM CELL CORPORATION 7,999,999 Shares of Common Stock This prospectus relates to the resale of up to 7,999,999 shares of our common stock by the selling stockholders named herein. On March 9, 2016, we entered into a securities purchase agreement with Sabby Healthcare Master Fund, Ltd., Sa |
|
| April 20, 2016 |
As filed with the Securities and Exchange Commission on April 20, 2016 S-1 Table of Contents As filed with the Securities and Exchange Commission on April 20, 2016 Registration No. |
|
| April 18, 2016 |
DEF 14A Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 18, 2016 |
ISCO / International Stem Cell Corp. / X-Master, Inc. - SCHEDULE 13D AMENDMENT Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 19) International Stem Cell Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 460378201 (CUSIP Number) Russell Kern a/k/a Ruslan Semechkin, President X-Master, Inc. 1 Overlook Drive, Unit 11 Amherst, New Ham |
|
| April 7, 2016 |
International Stem Cell PRE 14A PRE 14A Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 30, 2016 |
Exhibit 21.1 SUBSIDIARIES The following entities are owned directly or indirectly by the registrant: Name % Owned State of Incorporation or Organization International Stem Cell Corporation 100% California Lifeline Cell Technology, LLC 100% California Lifeline Skincare, Inc 100% California Cyto Therapeutics Pty. Ltd. 100% Victoria, Australia |
|
| March 30, 2016 |
Item UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K isco-10k20151231.htm Item UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-51891 INTERNATIONAL STEM C |
|
| March 30, 2016 |
Exhibit 10.9 THIRD AMENDMENT TO STANDARD MULTI-TENANT OFFICE LEASE - GROSS This Third Amendment to Standard Multi-Tenant Office Lease - Gross (?3rd Amendment?) is made and entered into as of this 29th day of February, 2016 by and between S Real Estate Holdings, LLC (?Lessor?) and International Stem Cell Corporation, a California corporation (?Lessee?), with reference to the following facts: A.Part |
|
| March 10, 2016 |
Entry into a Material Definitive Agreement Form 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 9, 2016 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commi |
|
| March 10, 2016 |
INTERNATIONAL STEM CELL CORPORATION PROMISSORY NOTE EX-10.1 Exhibit 10.1 INTERNATIONAL STEM CELL CORPORATION PROMISSORY NOTE FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, on this 9th day of March, 2016 (the ?Issuance Date?), International Stem Cell Corporation, a Delaware corporation (the ?Borrower?), hereby unconditionally promises to pay to the order of Andrey Semechkin or his assigns (the ?Noteholder?), the princi |
|
| March 10, 2016 |
EX-4.4 EXHIBIT 4.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| March 10, 2016 |
EX-10.2 Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of March , 2016, between International Stem Cell Corporation, a Delaware corporation (the ?Company?), and each of the several purchasers signatory hereto (each such purchaser, a ?Purchaser? and, collectively, the ?Purchasers?). This Agreement is made pursuant to the |
|
| March 10, 2016 |
EX-4.2 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| March 10, 2016 |
EX-10.3 Exhibit 10.3 March 9, 2016 STRICTLY CONFIDENTIAL International Stem Cell Corporation 5950 Priestly Drive Carlsbad, California 92008 Attn: Russell Kern, Executive Vice President Dear Sirs: This letter agreement (this ?Agreement?) constitutes the agreement between International Stem Cell Corporation (the ?Company?) and H.C. Wainwright & Co., LLC (?Wainwright?) that Wainwright shall serve as |
|
| March 10, 2016 |
EX-99.1 Exhibit 99.1 International Stem Cell Corporation to Raise $6.3 Million through a Private Placement to Fund Phase I Clinical Trial CARLSBAD, CA. - (Marketwired ? March 10, 2016), International Stem Cell Corporation (OTCQB: ISCO), a clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products , announced today it has entered into definitive agreemen |
|
| March 10, 2016 |
EX-4.3 Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| March 10, 2016 |
EX-3.2 Exhibit 3.2 INTERNATIONAL STEM CELL CORPORATION CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES I-2 CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, Andrey Semechkin and Mahnaz Ebrahimi, do hereby certify that: 1. They are the President and Secretary, respectively, of International Stem Cell Corporation, |
|
| March 10, 2016 |
EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of March 9, 2016, between International Stem Cell Corporation, a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the |
|
| March 10, 2016 |
8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 9, 2016 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commission |
|
| March 10, 2016 |
EX-3.1 Exhibit 3.1 INTERNATIONAL STEM CELL CORPORATION CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES I-1 CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, Andrey Semechkin and Mahnaz Ebrahimi, do hereby certify that: 1. They are the President and Secretary, respectively, of International Stem Cell Corporation, |
|
| March 10, 2016 |
EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| March 3, 2016 |
Form 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 3, 2016 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commi |
|
| January 12, 2016 |
Form 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 8, 2016 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Com |
|
| January 12, 2016 |
INTERNATIONAL STEM CELL CORPORATION PROMISSORY NOTE EX-10.1 Exhibit 10.1 INTERNATIONAL STEM CELL CORPORATION PROMISSORY NOTE FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, on this 8th day of January, 2016 (the ?Issuance Date?), International Stem Cell Corporation, a Delaware corporation (the ?Borrower?), hereby unconditionally promises to pay to the order of Andrey Semechkin or his assigns (the ?Noteholder?), the prin |
|
| January 12, 2016 |
EX-10.2 Exhibit 10.2 NOTE CONVERSION AGREEMENT THIS NOTE CONVERSION AGREEMENT (this ?Agreement?) is made as of January 8, 2016, by and among International Stem Cell Corporation, a Delaware corporation (the ?Company?), and Andrey Semechkin (the ?Holder?). RECITALS A. Holder is the Co-Chairman and Chief Executive Officer of the Company, and fully understands the present condition, opportunities and |
|
| January 12, 2016 |
EX-10.3 Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of January 8, 2016, between International Stem Cell Corporation, a Delaware corporation (the ?Company?), and Andrey Semechkin (the ?Purchaser?). This Agreement is made pursuant to the Note Conversion Agreement, dated as of the date hereof, between the Company and the |
|
| December 15, 2015 |
International Stem Cell FORM 8-K (Current Report/Significant Event) Form 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 10, 2015 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (C |
|
| December 15, 2015 |
INTERNATIONAL STEM CELL CORPORATION PROMISSORY NOTE EX-10.1 Exhibit 10.1 INTERNATIONAL STEM CELL CORPORATION PROMISSORY NOTE FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, on this 10th day of December, 2015 (the ?Issuance Date?), International Stem Cell Corporation, a Delaware corporation (the ?Borrower?), hereby unconditionally promises to pay to the order of Andrey Semechkin or his assigns (the ?Noteholder?), the pr |
|
| December 14, 2015 |
Exhibit 4.12 INTERATIONAL STEM CELL CORPORATION CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES I CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, Andrey Semechkin and Mahnaz Ebrahimi, do hereby certify that: 1. They are the Chief Executive Officer and Chief Financial Officer, respectively, of International Ste |
|
| December 14, 2015 |
Exhibit 4.14 COMMON STOCK PURCHASE WARRANT INTERNATIONAL STEM CELL CORPORATION Warrant Shares: [ Initial Exercise Date: , 2015 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date h |
|
| December 14, 2015 |
PLACEMENT AGENCY AGREEMENT December , 2015 Exhibit 1.1 PLACEMENT AGENCY AGREEMENT December , 2015 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this ?Agreement?), International Stem Cell Corporation, a Delaware corporation (the ?Company?), hereby agrees to sell up to an aggregate of $ of registered securities of the Company (the ?Securitie |
|
| December 14, 2015 |
Exhibit 10.41 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of , 2015, between International Stem Cell Corporation, a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and condi |
|
| December 14, 2015 |
International Stem Cell FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2015 International Stem Cell Corporation (Exact name of registrant as specified in its charter) Commission File Number: 000-51891 Delaware 20-4494098 (State or o |
|
| December 14, 2015 |
As filed with the Securities and Exchange Commission on December 14, 2015 Form S-1/A Table of Contents As filed with the Securities and Exchange Commission on December 14, 2015 Registration No. |
|
| December 14, 2015 |
Exhibit 4.13 COMMON STOCK PURCHASE WARRANT INTERNATIONAL STEM CELL CORPORATION Warrant Shares: [ Initial Exercise Date: , 2015 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date h |
|
| December 14, 2015 |
EX-99.1 Exhibit 99.1 International Stem Cell Corporation Receives Authorization to Initiate Phase I/IIa Clinical Trial of ISC-hpNSC for the Treatment of Parkinson?s Disease Regulatory submission (CTX) cleared for Phase I dose escalation trial in patients with moderate to severe Parkinson?s disease CARLSBAD, CA?(Marketwired ? December 14, 2015) - International Stem Cell Corporation (OTCQB: ISCO), a |
|
| December 4, 2015 |
International Stem Cell FORM 8-K (Current Report/Significant Event) Form 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 3, 2015 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Co |
|
| December 4, 2015 |
CERTIFICATE OF ELIMINATION OF THE SERIES H-2 PREFERRED STOCK OF INTERNATIONAL STEM CELL CORPORATION EX-3.2 Exhibit 3.2 CERTIFICATE OF ELIMINATION OF THE SERIES H-2 PREFERRED STOCK OF INTERNATIONAL STEM CELL CORPORATION Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware International Stem Cell Corporation, a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), in accordance with the provisions of Section 151(g) of the Gene |
|
| December 4, 2015 |
CERTIFICATE OF ELIMINATION OF THE SERIES H-1 PREFERRED STOCK OF INTERNATIONAL STEM CELL CORPORATION EX-3.1 Exhibit 3.1 CERTIFICATE OF ELIMINATION OF THE SERIES H-1 PREFERRED STOCK OF INTERNATIONAL STEM CELL CORPORATION Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware International Stem Cell Corporation, a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), in accordance with the provisions of Section 151(g) of the Gene |
|
| November 30, 2015 |
Form 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 23, 2015 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (C |
|
| November 25, 2015 |
As filed with the Securities and Exchange Commission on November 25, 2015 Form S-1/A Table of Contents As filed with the Securities and Exchange Commission on November 25, 2015 Registration No. |
|
| November 13, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-51891 INTERNATIONAL STEM |
|
| November 4, 2015 |
INTERNATIONAL STEM CELL CORPORATION PROMISSORY NOTE EX-10.1 Exhibit 10.1 INTERNATIONAL STEM CELL CORPORATION PROMISSORY NOTE FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, on this day of (the ?Issuance Date?), International Stem Cell Corporation, a Delaware corporation (the ?Borrower?), hereby unconditionally promises to pay to the order of Andrey Semechkin or his assigns (the ?Noteholder?), the principal amount of tw |
|
| November 4, 2015 |
Entry into a Material Definitive Agreement 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 3, 2015 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commiss |
|
| October 23, 2015 |
As filed with the Securities and Exchange Commission on October 23, 2015 POS AM Table of Contents As filed with the Securities and Exchange Commission on October 23, 2015 Registration No. |
|
| October 14, 2015 |
International Stem Cell FORM 8-K (Current Report/Significant Event) Form 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 9, 2015 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Com |
|
| October 14, 2015 |
INTERNATIONAL STEM CELL CORPORATION PROMISSORY NOTE EX-10.1 Exhibit 10.1 INTERNATIONAL STEM CELL CORPORATION PROMISSORY NOTE FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, on this day of (the ?Issuance Date?), International Stem Cell Corporation, a Delaware corporation (the ?Borrower?), hereby unconditionally promises to pay to the order of Andrey Semechkin or his assigns (the ?Noteholder?), the principal amount of tw |
|
| October 13, 2015 |
INTERNATIONAL STEM CELL CORPORATION 424B3 Filed Pursuant to 424(b)(3) Registration No. 333-201589 PROSPECTUS SUPPLEMENT TO PROSPECTUS DATED FEBRUARY 6, 2015 INTERNATIONAL STEM CELL CORPORATION This prospectus supplement supplements the prospectus dated February 6, 2015, relating to resale of up to 116,333,178 (pre-split) shares of our common stock by the selling stockholders named therein, and this supplement is qualified by referen |
|
| October 13, 2015 |
International Stem Cell FORM 8-K (Current Report/Significant Event) Form 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 10, 2015 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Co |
|
| September 14, 2015 |
8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 11, 2015 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commi |
|
| September 14, 2015 |
International Stem Cell FORM S-8 Form S-8 As filed with the Securities and Exchange Commission on September 14, 2015 Registration No. |
|
| September 9, 2015 |
INTERNATIONAL STEM CELL CORPORATION PROMISSORY NOTE EX-10.1 Exhibit 10.1 INTERNATIONAL STEM CELL CORPORATION PROMISSORY NOTE FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, on this 9th day of September, 2015 (the ?Issuance Date?), International Stem Cell Corporation, a Delaware corporation (the ?Borrower?), hereby unconditionally promises to pay to the order of Andrey Semechkin or his assigns (the ?Noteholder?), the pr |
|
| September 9, 2015 |
International Stem Cell 8-K (Current Report/Significant Event) 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 9, 2015 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commis |
|
| August 13, 2015 |
International Stem Cell FORM 8-K (Current Report/Significant Event) Form 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 10, 2015 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Com |
|
| August 13, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-51891 INTERNATIONAL STEM CELL |
|
| August 13, 2015 |
INTERNATIONAL STEM CELL CORPORATION PROMISSORY NOTE EX-10.1 Exhibit 10.1 INTERNATIONAL STEM CELL CORPORATION PROMISSORY NOTE FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, on this 10th day of August, 2015 (the ?Issuance Date?), International Stem Cell Corporation, a Delaware corporation (the ?Borrower?), hereby unconditionally promises to pay to the order of Andrey Semechkin or his assigns (the ?Noteholder?), the prin |
|
| August 11, 2015 |
International Stem Cell FORM 8-K (Current Report/Significant Event) Form 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 5, 2015 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Comm |
|
| July 28, 2015 |
EX-3.1 Exhibit 3.1 Delaware PAGE 1 The First State I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF ?INTERNATIONAL STEM CELL CORPORATION?, FILED IN THIS OFFICE ON THE TWENTY-SECOND DAY OF JULY, A.D. 2015, AT 6:51 O?CLOCK P.M. A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW |
|
| July 28, 2015 |
International Stem Cell FORM 8-K (Current Report/Significant Event) Form 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 22, 2015 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commi |
|
| June 24, 2015 |
As filed with the Securities and Exchange Commission on June 24, 2015 Form S-1 Table of Contents As filed with the Securities and Exchange Commission on June 24, 2015 Registration No. |
|
| June 5, 2015 |
8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 3, 2015 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commission |
|
| May 14, 2015 |
International Stem Cell FORM 8-K (Current Report/Significant Event) Form 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 12, 2015 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commis |
|
| May 14, 2015 |
INTERNATIONAL STEM CELL CORPORATION PROMISSORY NOTE EX-10.1 Exhibit 10.1 INTERNATIONAL STEM CELL CORPORATION PROMISSORY NOTE FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, on this 12th day of May, 2015 (the ?Issuance Date?), International Stem Cell Corporation, a Delaware corporation (the ?Borrower?), hereby unconditionally promises to pay to the order of Andrey Semechkin or his assigns (the ?Noteholder?), the princip |
|
| May 11, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-51891 INTERNATIONAL STEM CEL |
|
| May 11, 2015 |
Submission of Matters to a Vote of Security Holders Form 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 7, 2015 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commiss |
|
| May 11, 2015 |
FIRST AMENDMENT TO SERIES B COMMON STOCK PURCHASE WARRANT FIRST AMENDMENT TO SERIES B COMMON STOCK PURCHASE WARRANT This First Amendment (the ?Amendment?) to Series B Common Stock Purchase Warrant (the ?Warrant?), is made and entered into effective as of April 14, 2015 (the ?Effective Date?), by and between International Stem Cell Corporation, a Delaware corporation (the ?Company?) and (the ?Holder?). |
|
| May 8, 2015 |
International Stem Cell FORM 8-K (Current Report/Significant Event) Form 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 6, 2015 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Commiss |
|
| May 8, 2015 |
INTERNATIONAL STEM CELL CORPORATION PROMISSORY NOTE EX-10.1 Exhibit 10.1 INTERNATIONAL STEM CELL CORPORATION PROMISSORY NOTE FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, International Stem Cell Corporation, a Delaware corporation (the ?Borrower?), hereby unconditionally promises to pay to the order of Andrey Semechkin or his assigns (the ?Noteholder?), the principal amount of two-hundred and sixty-two thousand Dolla |
|
| April 30, 2015 |
Form 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 27, 2015 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Comm |
|
| April 23, 2015 |
Form 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 22, 2015 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Comm |
|
| April 15, 2015 |
INTERNATIONAL STEM CELL CORPORATION 77,555,452 Shares of Common Stock 424B3 Filed Pursuant to 424(b)(3) Registration No. 333-199779 PROSPECTUS SUPPLEMENT TO PROSPECTUS DATED NOVEMBER 25, 2014 INTERNATIONAL STEM CELL CORPORATION 77,555,452 Shares of Common Stock This prospectus supplement supplements the prospectus dated November 25, 2014, relating to resale of up to 77,555,452 shares of our common stock by the selling stockholders named therein, and this supplement |
|
| April 15, 2015 |
INTERNATIONAL STEM CELL CORPORATION 116,333,178 Shares of Common Stock 424B3 Filed Pursuant to 424(b)(3) Registration No. 333-201589 PROSPECTUS SUPPLEMENT TO PROSPECTUS DATED FEBRUARY 6, 2015 INTERNATIONAL STEM CELL CORPORATION 116,333,178 Shares of Common Stock This prospectus supplement supplements the prospectus dated February 6, 2015, relating to resale of up to 116,333,178 shares of our common stock by the selling stockholders named therein, and this supplement |
|
| April 15, 2015 |
Form 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 14, 2015 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Comm |
|
| April 10, 2015 |
ISCO / International Stem Cell Corp. / X-Master, Inc. - SCHEDULE 13D AMENDMENT Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 18) International Stem Cell Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 05577Y107 (CUSIP Number) Ruslan Semechkin, President X-Master, Inc. 1 Overlook Drive, Unit 11 Amherst, New Hampshire 03031 Tel. ( |
|
| April 1, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 31, 2015 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Comm |
|
| April 1, 2015 |
International Stem Cell Corporation Announces 2014 Fourth Quarter and Year-End Results EX-99.1 Exhibit 99.1 International Stem Cell Corporation Announces 2014 Fourth Quarter and Year-End Results CARLSBAD, CA - (Marketwired) ? March 31, 2015, International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) (?ISCO? or ?the Company?), a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business u |
|
| March 31, 2015 |
International Stem Cell FORM DEF 14A Form DEF 14A Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 30, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-51891 INTERNATIONAL STEM CELL CORPORATION (Exact nam |
|
| March 30, 2015 |
Exhibit 21.1 SUBSIDIARIES The following entities are owned directly or indirectly by the registrant: Name % Owned State of Incorporation or Organization International Stem Cell Corporation 100% California Lifeline Cell Technology, LLC 100% California Lifeline Skincare, Inc 100% California Cyto Therapeutics Pty. Ltd. 100% Victoria, Australia |
|
| March 30, 2015 |
Exhibit 10.32 WAIVER AGREEMENT This Waiver Agreement (the ?Agreement?) is entered into as of December 31, 2014, by and between International Stem Cell Corporation, a Delaware corporation (the ?Company?), and Andrey Semechkin, an individual, Ruslan Semechkin, an individual, and AR Partners, LLC, a Delaware limited liability company (collectively, the ?Holders?) with respect to the following: A.The |
|
| March 23, 2015 |
International Stem Cell FORM 8-K (Current Report/Significant Event) Form 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 18, 2015 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Comm |
|
| March 5, 2015 |
International Stem Cell SCHEDULE 13D AMENDMENT (Activist Acquisition of More Than 5% of Shares) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 17) International Stem Cell Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 05577Y107 (CUSIP Number) Ruslan Semechkin, President X-Master, Inc. 1 Overlook Drive, Unit 11 Amherst, New Hampshire 03031 Tel. ( |
|
| February 13, 2015 |
ISCO / International Stem Cell Corp. / CAPITAL VENTURES INTERNATIONAL - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* International Stem Cell Corporation (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 05577Y107 (CUSIP Number) Dece |
|
| February 6, 2015 |
INTERNATIONAL STEM CELL CORPORATION 116,333,178 Shares of Common Stock 424B3 Table of Contents Filed pursuant to 424(b)(3) Registration No. 333-201589 PROSPECTUS INTERNATIONAL STEM CELL CORPORATION 116,333,178 Shares of Common Stock This prospectus relates to the resale of up to 116,333,178 shares of our common stock by the selling stockholders named herein. On October 7, 2014, we entered into a securities purchase agreement with Sabby Healthcare Volatility Master Fu |
|
| January 23, 2015 |
ISCO / International Stem Cell Corp. / X-Master, Inc. - AMENDMENT NO. 16 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 16) International Stem Cell Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 05577Y107 (CUSIP Number) Ruslan Semechkin, President X-Master, Inc. 1 Overlook Drive, Unit 11 Amherst, New Hampshire 03031 Tel. ( |
|
| January 16, 2015 |
ISCO / International Stem Cell Corp. S-1 - Registration Statement - S-1 S-1 Table of Contents As filed with the Securities and Exchange Commission on January 16, 2015 Registration No. |
|
| January 16, 2015 |
EX-10.54 Exhibit 10.54 WAIVER AGREEMENT This Waiver Agreement (the “Agreement”) is entered into as of December 31, 2014, by and between International Stem Cell Corporation, a Delaware corporation (the “Company”), and Andrey Semechkin, an individual, Ruslan Semechkin, an individual, and AR Partners, LLC, a Delaware limited liability company (collectively, the “Holders”) with respect to the followin |
|
| January 7, 2015 |
EX-99.1 Exhibit 99.1 International Stem Cell Corporation and Subsidiaries Condensed Pro Forma Consolidated Balance Sheet (in thousands, except share data) September 30, 2014 Pro Forma September 30, 2014 As Reported Adjustments Pro Forma (Unaudited) (Unaudited) (Unaudited) Assets Cash and cash equivalents $ 471 $ — $ 471 Accounts receivable, net of allowance for doubtful accounts of $19 464 — 464 I |
|
| January 7, 2015 |
Form 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 31, 2014 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (C |
|
| December 29, 2014 |
Form 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 22, 2014 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (C |
|
| December 5, 2014 |
EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF INTERNATIONAL STEM CELL CORPORATION International Stem Cell Corporation, a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify: FIRST: On October 7, 2014, the Board of Directors of the Corporation duly adopted resolut |
|
| December 5, 2014 |
Form 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 4, 2014 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (Co |
|
| November 25, 2014 |
INTERNATIONAL STEM CELL CORPORATION 77,555,452 Shares of Common Stock 424B4 Table of Contents Filed Pursuant to 424(b)(4) Registration File No. 333-199779 PROSPECTUS INTERNATIONAL STEM CELL CORPORATION 77,555,452 Shares of Common Stock This prospectus relates to the resale of up to 77,555,452 shares of our common stock by the selling stockholders named herein. On October 7, 2014, we entered into a securities purchase agreement with Sabby Healthcare Volatility Master |
|
| November 21, 2014 |
ISCO / International Stem Cell Corp. S-1/A - - S-1/A S-1/A Table of Contents As filed with the Securities and Exchange Commission on November 21, 2014 Registration No. |
|
| November 18, 2014 |
EX-10.1 Exhibit 10.1 AMENDMENT TO AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT This Amendment (the “Amendment”) is entered into as of November 13, 2014 with respect to the Amended and Restated Investor Rights Agreement (the “Rights Agreement”) dated as of March 9, 2012. WHEREAS, the Company and the Investors (as defined in the Rights Agreement) entered into the Rights Agreement to provide, among |
|
| November 18, 2014 |
Form 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 13, 2014 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (C |
|
| November 13, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-51891 INTERNATIONAL STEM |
|
| November 13, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 13, 2014 INTERNATIONAL STEM CELL CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51891 20-4494098 (State or other jurisdiction of incorporation) (C |
|
| November 13, 2014 |
EX-99.1 Exhibit 99.1 International Stem Cell Corporation Announces Record Revenues and Significant Progress in R&D Will host conference call at 11 am ET on November 14, 2014 CARLSBAD, CA., November 13, 2014, International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell based therapies and biomedical products today provided a business update |
|
| November 5, 2014 |
ISCO / International Stem Cell Corp. / X-Master, Inc. - AMENDMENT NO. 15 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 15) International Stem Cell Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 05577Y107 (CUSIP Number) Ruslan Semechkin, President X-Master, Inc. 1 Overlook Drive, Unit 11 Amherst, New Hampshire 03031 Tel. ( |
|
| November 3, 2014 |
ISCO / International Stem Cell Corp. DEFA14A - - DEFA14A DEFA14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
